Here's Why Sage Therapeutics Lost 53.3% in December

Shares of Sage Therapeutics (NASDAQ: SAGE) fell by more than half last month, according to data provided by S&P Global Market Intelligence. The nosedive occurred after the company announced that SAGE-217 failed a phase 3 study investigating the drug candidate's potential to treat major depressive disorder (MDD).